Whoa thread jacked lol.. it's no problem. Yeah I wanted to get xtren but the price really made it not worth it, the GOD of all tren I would have to say is Trenadrol. I couldn't believe the gains I got on that stuff, by far hands down the best. Wish a clone could of been made, but no one knows the real chemical combo, since the one on the label was false lol.
Anywho, the reason I choose torem is from what I've heard and experienced. I have used torem in my last two cycles which I couldn't believe how quickly the stuff works. Testes bounce right back, and libido increases a lot more quickly. What I like about it, is it does not negatively affect cholesterol like Nolvadex does, nor igf levels. Side effects are also more rare with torem.
Here's some sources about Torem:
Fareston
Chemical Name: Toremifene Citrate
Drug Class: Selective Estrogen Receptor Modulator
Fareston is a Selective Estrogen Receptor Modulator (SERM), not unlike its more popular cousins Nolvadex and Clomid. Just as we see with Nolvadex, Fareston is used to treat breast cancer in post-menopausal women. It does this by exerting estrogen antagonistic effects in certain tissue, most notably, breast tissue. This is actually the same mechanism of action found in Nolvadex. This is why Nolvadex is often recommended to bodybuilders who are trying to avoid gynocomastia (growth of breast tissue in males). SERMs, in addition, have several other well known effects in men, which are not simply limited to preventing the abnormal growth of breast tissue.
At the hypothalamus and pituitary, estrogen acts in cooperation with the male body’s negative feedback loop to send a signal to decrease the secretion of LH, and when LH secretion is lowered, so are natural testosterone levels. SERMs, like Fareston, possibly act as an estrogen antagonist in the hypothalamus and pituitary, in order to increase testosterone production. Thus, although it hasn’t been studied to any great degree, it’s highly likely that Fareston is capable of increasing testosterone in the same way that Nolvadex it, as it’s androgenicity:estrogenicity ratio is 5x that of Nolvadex(1). It may also be better than Nolvadex for reasons that are of particular interest to steroid using athletes and bodybuilders.
Fareston differs from Nolvadex in several ways, however- even though it’s very similar to it in others. Firstly, the risk of certain side effects (although relatively rare with Nolvadex) is actually quite a bit lower with Fareston.However unlikely these risks are in the first place, the risk of stroke, pulmonary embolism, and cataract is probably lower with Fareston than with Nolvadex. This is going to be of interest to people who have issues with “floaters” in their vision, which is sometimes caused by Nolvadex and Clomid, as this product may represent significantly less occular toxicity. It also differs slightly from Nolvadex in its potent with regards to improving lipid (cholesterol) profiles. In terms of improving bone mineral density, Fareston is roughly equal to Nolvadex.(2)
Although anecdotal evidence on this compound is rare, bodybuilders who have already experimented with this stuff seem satisfied. In my estimation, it would seem to be a more potent and safer alternative to Nolvadex, for those who are worried about side effects. I’m also predicting that it may provide a greater increase in LH and therefore testosterone levels, in men when compared to Nolvadex (when an appropriate dose of each is utilized). This makes its use a strong possibility for PCT in the future, when studies on its ability to elevate testosterone is more fully studied and understood.
Fareston would also make a welcome addition to a cycle where Cholesterol issues may be a concern, or where something slightly stronger than Nolvadex may be required to prevent gyno.
References:
1. Breast Cancer Re Treat. 1990 Aug;16 Suppl:S3-7. Introduction to toremifene. Kangas L.
2. Breast 2006 Apr;15(2):142-57. Epub 2005 Nov 9.Toremifene: An evaluation of its safety profile. Harvey HA, Kimura , MHajba A
-------------------------------------------------
ASCO: Fareston (Toremifene Citrate) as Effective as Tamoxifen in Breast Cancer
NEW ORLEANS, LA -- May 23, 2000 -- Data presented at the 36th Annual American Society of Clinical Oncology meeting, demonstrate that the use of Shire Roberts' Fareston (toremifene citrate) as adjuvant treatment for breast cancer in post-menopausal women is at least as safe and effective as tamoxifen. The trial, conducted by The Finnish Breast Cancer Group, is the first clinical trial to compare the efficacy and safety of Fareston to tamoxifen in the adjuvant treatment setting for post-menopausal women with axillary node-positive breast cancer.
"The results of this study are of significant importance because they show that Fareston is as effective as tamoxifen in the adjuvant treatment of breast cancer," said Dr. Kaija Holli, Professor, Department of Oncology at Tampere University Hospital and Lead Investigator for the Finnish Breast Cancer Group trial.
One-thousand-four-hundred and eighty patients were randomized into one of two groups receiving Fareston (40 mg/day) or tamoxifen (20 mg/day: 2-10 mg doses/day) for three years. The average follow-up time for the 899 patients included in the interim analysis presented today was 3.4 years. According to data presented the subjective side effect profile was similar (no statistically significant difference) in both treatment groups (i.e.: sweating and hot flashes) as well as the mean time to breast cancer recurrence. However, the breast cancer recurrence rate and death from breast cancer was lower in the Fareston treatment group (23.1 percent and 5.3 percent, respectively) compared to the tamoxifen treatment group (26.1 percent and 9.6 percent).
Fareston is an anti-estrogenic treatment for breast cancer that has been available in the U.S. since 1997. It is currently indicated for the treatment of metastatic breast cancer in post-menopausal women with estrogen receptor positive or unknown tumors.
"This is very exciting news about Fareston because it suggests that this product may provide patients with an alternative treatment option with a good safety profile and potential cost benefits," said Dr. Michael J. Edwards, Associate Professor, Department of Surgery, Division of Surgical Oncology at the University of Louisville and Chairman of the North American Fareston versus Tamoxifen Adjuvant trial for Breast Cancer (NAFTA trial). "These results are promising and I look forward to continuing to work with my colleagues in the U.S. on the NAFTA trial, which should provide additional support of Fareston as a safe and effective adjuvant treatment for breast cancer in comparison to the current standard of care."
The North American Fareston versus Tamoxifen Adjuvant trial for Breast Cancer (NAFTA trial) was initiated in 1998 to compare the clinical efficacy and safety profile of Fareston adjuvant treatment to tamoxifen adjuvant treatment. The NAFTA trial is designed to have 1,980 participants randomized to receive Fareston (60 mg/day) for five years or tamoxifen (20 mg/day) for five years, with a five-year follow-up. The NAFTA trial currently has 114 clinical investigation sites recruiting patient participation
"We are very pleased with the results of this study that will reinforce what is known about the efficacy and safety of Fareston therapy," said Simon Tulloch, MD, Senior Vice President of Research and Development for Shire Pharmaceutical Development in the USA. "Shire is committed to ensuring that all patients who need and want to take Fareston have access to the medication."
Shire Pharmaceuticals Group is an international specialty pharmaceutical company with a strategic focus on four therapeutic areas: central nervous system disorders, metabolic diseases, oncology, and gastroenterology. Shire has sales and marketing infrastructure supporting a broad portfolio of products in the United States, Canada, United Kingdom, Republic of Ireland, France, Germany, and Italy. Shire's global search and development expertise has already provided three marketed products, while the current pipeline of thirteen projects includes one product in registration and a significant number advanced beyond Phase II. In 1999, Shire merged with Roberts Pharmaceutical Corporation.